Manufacturers in the cholesterol lowering drugs market are increasing research activities to include bempedoic acid for the development of new drugs. For instance, in May 2019, Esperion - a U.S. pharmaceutical company, announced the FDA approval for new drug applications (NDAs) involving the bempedoic acid.
Companies are harnessing the advantages of bempedoic acid to treat a host of health conditions such as hypercholesterolemia and to treat patients with high cardiovascular risks. As such, the hypercholesterolemia indication segment of the cholesterol lowering drugs market is projected to reach a value of ~US$ 19.6 Bn by 2027. Hence, healthcare providers in the market for cholesterol lowering drugs are recommending the intake of bempedoic acid with statins to lower complications of LDL (Low-density Lipoproteins) associated with hypercholesterolemia.
Growing awareness about bad cholesterol is one of the key drivers that is triggering the growth of the cholesterol lowering drugs market. Companies are referring investigational studies to understand which drugs are well-tolerated in patients and make improvements according to the results.
In order to improve cardiovascular risk assessment, companies are increasingly adopting the ‘personalized’ approach to achieve better outcomes in patients. This trend has led to the concept of precision medicine in the market for cholesterol lowering drugs. The coronary artery disease indication segment of the cholesterol lowering drugs market is estimated to reach a value of ~US$ 14.9 Bn by 2027. Hence, manufacturers are increasing clinical trials that show promising outcomes of PCSK9 inhibitor monoclonal antibodies for the treatment of coronary artery diseases.
Companies in the cholesterol lowering drugs market are increasing their production capacities to manufacture Evolocumab used by high-risk patients. They are also tapping into opportunities to manufacture Canakinumbab, an effective antibody that leads to significant decline in cardiovascular events. Manufacturers are developing improved PCSK9 inhibitors to treat hyperchoesterolaemia. They are focusing on secondary prevention statins to lower LDL-C in patients. Improved outcomes associated with CPSK9 inhibitors are translating into revenue sources for companies in the market for cholesterol lowering drugs.
Various clinical trials have concluded that bile acid biosynthesis helps in reverse cholesterol transport (RCT). In a research published in MDPI, an open access publishing platform for scholarly research studies, reveals that RCT helps in reducing cholesterol via its conversion into bile acids in patients. On the other hand, companies are entering into licensing agreements to bolster their credibility credentials in the global cholesterol lowering drugs market. For instance, in January 2019, global pharmaceutical company Daiichi Sankyo Europe announced its European licensing agreement with Esperion, to market bempedoic acid and Ezetimibe combination tablet for cholesterol patients.
Strategic agreements are helping manufacturers to expand their cardiovascular portfolio, since cholesterol increases risks of coronary heart diseases. Companies are eyeing business expansions in the U.K. and Switzerland. Patients are increasingly benefitting from the advantages of bempedoic-induced drugs, as novel drug help to reduce fatty acid synthesis in liver.
Statins & combination drug class segment of the cholesterol lowering drugs market is expected to reach a value of ~US$ 19.8 Bn by 2021. However, side effects associated with statins, such as muscle pain and undesired reactions with other medicines, act as a barrier for its adoption by patients. Hence, manufacturers are introducing new class of oral cholesterol lowering drugs that are well tolerated in patients.
Improved drug formulations in new oral drugs are being used as an alternative to statins. Manufacturers in the cholesterol lowering drugs market are increasing production capabilities to include bempedoic acid in new drug formulations. They are increasing efforts to obtain approvals for bempedoic-induced drugs in Europe.
Moreover, companies in the market for cholesterol lowering drugs are increasing research activities to develop drugs using bempedoic acid to reduce incidences of heart attack and stroke in patients. High prevalence of LDL cholesterol is another driver fueling the demand for cholesterol lowering drugs.
Analysts’ Viewpoint
Top medical innovations in the cholesterol lowering drugs market primarily involve bempedoic acid in drug formulations. Apart from North America and Europe, manufacturers are leveraging opportunities in Asia Pacific, since governments of rapidly developing countries are increasingly investing toward the strengthening of their healthcare infrastructure.
Though statins are projected for widespread adoption in the coming years, its side effects are a major concern for healthcare companies. Hence, companies in the cholesterol lowering drugs market should increase awareness about the intake of statins with Ezetimibe or PCSK9 inhibitors to reduce LDL-C and boost drug tolerance in patients. They should increase production of PCSK9 inhibitors, since these drugs are anticipated to witness high adoption during the forecast period.
Cholesterol lowering drugs market to reach a valuation of ~US$ 37.7 Bn by 2027
Cholesterol lowering drugs market is expected to expand at a CAGR of ~3% during the forecast period from 2019 to 2027
Cholesterol lowering drugs market is driven by increase in prevalence of coronary artery disease
North America accounted for a major share of the cholesterol lowering drugs market, and is projected to remain dominant during the forecast period
Key players in the cholesterol lowering drugs market include Sanofi, Pfizer, Inc., GlaxoSmithKline plc, Novartis AG, Merck & Co., Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Cholesterol Lowering Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Drug Class Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Cholesterol Lowering Drugs Market Analysis and Forecasts, 2017–2027
5. Market Outlook
5.1. Pipeline Analysis
5.2. Key Drug Brand Analysis
5.3. Key Merger & Acquisitions
5.4. Pipeline Analysis
5.5. Global Prevalence of Cardiovascular Diseases
6. Global Cholesterol Lowering Drugs Market Analysis and Forecasts, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Class, 2017–2027
6.3.1. Statins and Combination
6.3.2. PCSK9 Inhibitors
6.3.3. Bile Acid Sequestrants
6.3.4. Fibrates
6.3.5. Cholesterol Absorption Inhibitors
6.3.6. Others
6.4. Market Attractiveness, by Drug Class
7. Global Cholesterol Lowering Drugs Market Analysis and Forecasts, by Indication
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Indication, 2017–2027
7.3.1. Hypercholesterolemia
7.3.2. Coronary Artery Disease
7.3.3. Higher Triglycerides
7.4. Market Attractiveness, by Indication
8. Global Cholesterol Lowering Drugs Market Analysis and Forecasts, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2027
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness, by Distribution Channel
9. Global Cholesterol Lowering Drugs Market Analysis and Forecasts, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness, by Region
10. North America Cholesterol Lowering Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug Class, 2017–2027
10.2.1. Statins and Combination
10.2.2. PCSK9 Inhibitors
10.2.3. Bile Acid Sequestrants
10.2.4. Fibrates
10.2.5. Cholesterol Absorption Inhibitors
10.2.6. Others
10.3. Market Value Forecast, by Indication, 2017–2027
10.3.1. Hypercholesterolemia
10.3.2. Coronary Artery Disease
10.3.3. Higher Triglycerides
10.4. Market Value Forecast, by Distribution Channel, 2017–2027
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Market Value Forecast, by Country, 2017–2027
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Drug Class
10.6.2. By Indication
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Cholesterol Lowering Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Class, 2017–2027
11.2.1. Statins and Combination
11.2.2. PCSK9 Inhibitors
11.2.3. Bile Acid Sequestrants
11.2.4. Fibrates
11.2.5. Cholesterol Absorption Inhibitors
11.2.6. Others
11.3. Market Value Forecast, by Indication, 2017–2027
11.3.1. Hypercholesterolemia
11.3.2. Coronary Artery Disease
11.3.3. Higher Triglycerides
11.4. Market Value Forecast, by Distribution Channel, 2017–2027
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Market Value Forecast, by Country/Sub-region, 2017–2027
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Drug Class
11.6.2. By Indication
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Cholesterol Lowering Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2017–2027
12.2.1. Statins and Combination
12.2.2. PCSK9 Inhibitors
12.2.3. Bile Acid Sequestrants
12.2.4. Fibrates
12.2.5. Cholesterol Absorption Inhibitors
12.2.6. Others
12.3. Market Value Forecast, by Indication, 2017–2027
12.3.1. Hypercholesterolemia
12.3.2. Coronary Artery Disease
12.3.3. Higher Triglycerides
12.4. Market Value Forecast, by Distribution Channel, 2017–2027
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Market Value Forecast, by Country/Sub-region, 2017–2027
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Drug Class
12.6.2. By Indication
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Cholesterol Lowering Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2017–2027
13.2.1. Statins and Combination
13.2.2. PCSK9 Inhibitors
13.2.3. Bile Acid Sequestrants
13.2.4. Fibrates
13.2.5. Cholesterol Absorption Inhibitors
13.2.6. Others
13.3. Market Value Forecast, by Indication, 2017–2027
13.3.1. Hypercholesterolemia
13.3.2. Coronary Artery Disease
13.3.3. Higher Triglycerides
13.4. Market Value Forecast, by Distribution Channel, 2017–2027
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Market Value Forecast, by Country/Sub-region, 2017–2027
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Drug Class
13.6.2. By Indication
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Cholesterol Lowering Drugs Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Class, 2017–2027
14.2.1. Statins and Combination
14.2.2. PCSK9 Inhibitors
14.2.3. Bile Acid Sequestrants
14.2.4. Fibrates
14.2.5. Cholesterol Absorption Inhibitors
14.2.6. Others
14.3. Market Value Forecast, by Indication, 2017–2027
14.3.1. Hypercholesterolemia
14.3.2. Coronary Artery Disease
14.3.3. Higher Triglycerides
14.4. Market Value Forecast, by Distribution Channel, 2017–2027
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Market Value Forecast, by Country/Sub-region, 2017–2027
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Drug Class
14.6.2. By Indication
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of companies)
15.2. Market Share Analysis/Ranking, by Company (2018)
15.3. Company Profiles
15.3.1. Pfizer Inc.
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Company Financials
15.3.1.3. Growth Strategies
15.3.1.4. SWOT Analysis
15.3.2. Sanofi
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Company Financials
15.3.2.3. Growth Strategies
15.3.2.4. SWOT Analysis
15.3.3. GlaxoSmithKline plc
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Company Financials
15.3.3.3. Growth Strategies
15.3.3.4. SWOT Analysis
15.3.4. Novartis AG
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Company Financials
15.3.4.3. Growth Strategies
15.3.4.4. SWOT Analysis
15.3.5. Merck & Co., Inc.
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Company Financials
15.3.5.3. Growth Strategies
15.3.5.4. SWOT Analysis
15.3.6. Amgen, Inc.
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Company Financials
15.3.6.3. Growth Strategies
15.3.6.4. SWOT Analysis
15.3.7. Takeda Pharmaceutical Company Limited
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Company Financials
15.3.7.3. Growth Strategies
15.3.7.4. SWOT Analysis
15.3.8. Sun Pharmaceutical Industries Ltd.
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Company Financials
15.3.8.3. Growth Strategies
15.3.8.4. SWOT Analysis
15.3.9. AbbVie, Inc.
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Company Financials
15.3.9.3. Growth Strategies
15.3.9.4. SWOT Analysis
15.3.10. Mylan N.V.
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Company Financials
15.3.10.3. Growth Strategies
15.3.10.4. SWOT Analysis
List of Tables
Table 01: Key Pipeline Analysis – Cholesterol Lowering Drugs Market
Table 02: Key Brand Sales Analysis – Cholesterol Lowering Drugs Market
Table 03: Key Mergers & Acquisition in the Cholesterol Lowering Drugs Market
Table 04: Global Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 05: Global Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast, by Indication, 2017–2027
Table 06: Global Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 07: Global Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast, by Region, 2017–2027
Table 08: North America Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast, by Country, 2017–2027
Table 09: North America Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 10: North America Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast, by Indication, 2017–2027
Table 11: North America Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 12: Europe Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 13: Europe Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 14: Europe Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast, by Indication, 2017–2027
Table 15: Europe Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 16: Asia Pacific Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 17: Asia Pacific Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 18: Asia Pacific Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast, by Indication, 2017–2027
Table 19: Asia Pacific Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 20: Latin America Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 21: Latin America Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 22: Latin America Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast, by Indication, 2017–2027
Table 23: Latin America Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 24: Middle East & Africa Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 25: Middle East & Africa Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 26: Middle East & Africa Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast, by Indication, 2017–2027
Table 27: Middle East & Africa Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
List of Figures
Figure 01: Global Cholesterol Lowering Drugs Market Value (US$ Mn) and Distribution (%), by Region, 2018 and 2027
Figure 02: Global Cholesterol Lowering Drugs Market Value (US$ Mn), by Drug Class, 2018
Figure 03: Global Cholesterol Lowering Drugs Market Value Share Analysis, by Drug Class, 2018
Figure 04: Market Overview
Figure 05: Global Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast, 2017–2027
Figure 06: Global Cholesterol Lowering Drugs Market Value Share, by Drug Class, 2018
Figure 07: Global Cholesterol Lowering Drugs Market Value Share, by Indication, 2018
Figure 08: Global Cholesterol Lowering Drugs Market Value Share, by Distribution Channel, 2018
Figure 09: Global Cholesterol Lowering Drugs Market Value Share, by Region, 2018
Figure 10: Demographic Cardiovascular Death Statistics Globally-2017 (Millions)
Figure 11: Global Cholesterol Lowering Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 12: Global Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Statins & Combination, 2017-2027
Figure 13: Global Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by PCSK9 Inhibitors, 2017-2027
Figure 14: Global Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Bile Acid Sequestrants, 2017-2027
Figure 15: Global Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Fibrates, 2017-2027
Figure 16: Global Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Cholesterol Absorption Inhibitors, 2017-2027
Figure 17: Global Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017-2027
Figure 18: Global Cholesterol Lowering Drugs Market Attractiveness, by Drug Class, 2019–2027
Figure 19: Global Cholesterol Lowering Drugs Market Value Share Analysis, by Indication, 2018 and 2027
Figure 20: Global Cholesterol Lowering Drugs Market Value (US$ Mn) and Y-o-Y Growth, by Hypercholesterolemia, 2017–2027
Figure 21: Global Cholesterol Lowering Drugs Market Value (US$ Mn) and Y-o-Y Growth, by Coronary Artery Disease, 2017–2027
Figure 22: Global Cholesterol Lowering Drugs Market Value (US$ Mn) and Y-o-Y Growth, by Higher Triglycerides, 2017–2027
Figure 23: Global Cholesterol Lowering Drugs Market Attractiveness Analysis, by Indication, 2019–2027
Figure 24: Global Cholesterol Lowering Drugs Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 25: Global Cholesterol Lowering Drugs Market Value (US$ Mn) and Y-o-Y Growth, by Hospital Pharmacies, 2017–2027
Figure 26: Global Cholesterol Lowering Drugs Market Value (US$ Mn) and Y-o-Y Growth, by Retail Pharmacies, 2017–2027
Figure 27: Global Cholesterol Lowering Drugs Market Value (US$ Mn) and Y-o-Y Growth, by Online Pharmacies, 2017–2027
Figure 28: Global Cholesterol Lowering Drugs Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 29: Global Cholesterol Lowering Drugs Market Value Share Analysis, by Region, 2018 and 2027
Figure 30: Global Cholesterol Lowering Drugs Market Attractiveness Analysis, by Region, 2019–2027
Figure 31: North America Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
Figure 32: North America Cholesterol Lowering Drugs Market Value Share, by Country, 2018 and 2027
Figure 33: North America Cholesterol Lowering Drugs Market Attractiveness, by Country, 2019–2027
Figure 34: North America Cholesterol Lowering Drugs Market Value Share, by Drug Class, 2018 and 2027
Figure 35: North America Cholesterol Lowering Drugs Market Attractiveness, by Drug Class, 2019–2027
Figure 36: North America Cholesterol Lowering Drugs Market Value Share, by Indication, 2018 and 2027
Figure 37: North America Cholesterol Lowering Drugs Market Attractiveness, by Indication, 2019–2027
Figure 38: North America Cholesterol Lowering Drugs Market Value Share, by Distribution Channel, 2018 and 2027
Figure 39: North America Cholesterol Lowering Drugs Market Attractiveness, by Distribution Channel, 2019–2027
Figure 40: Europe Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
Figure 41: Europe Cholesterol Lowering Drugs Market Value Share, by Country/Sub-region, 2018 and 2027
Figure 42: Europe Cholesterol Lowering Drugs Market Attractiveness, by Country/Sub-region, 2019–2027
Figure 43: Europe Cholesterol Lowering Drugs Market Value Share, by Drug Class, 2018 and 2027
Figure 44: Europe Cholesterol Lowering Drugs Market Attractiveness, by Drug Class, 2019–2027
Figure 45: Europe Cholesterol Lowering Drugs Market Value Share, by Indication, 2018 and 2027
Figure 46: Europe Cholesterol Lowering Drugs Market Attractiveness, by Indication, 2019–2027
Figure 47: Europe Cholesterol Lowering Drugs Market Value Share, by Distribution Channel, 2018 and 2027
Figure 48: Europe Cholesterol Lowering Drugs Market Attractiveness, by Distribution Channel, 2019–2027
Figure 49: Asia Pacific Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
Figure 50: Asia Pacific Cholesterol Lowering Drugs Market Value Share, by Country/Sub-region, 2018 and 2027
Figure 51: Asia Pacific Cholesterol Lowering Drugs Market Attractiveness, by Country/Sub-region, 2019–2027
Figure 52: Asia Pacific Cholesterol Lowering Drugs Market Value Share, by Drug Class, 2018 and 2027
Figure 53: Asia Pacific Cholesterol Lowering Drugs Market Attractiveness, by Drug Class, 2019–2027
Figure 54: Asia Pacific Cholesterol Lowering Drugs Market Value Share, by Indication, 2018 and 2027
Figure 55: Asia Pacific Cholesterol Lowering Drugs Market Attractiveness, by Indication, 2019–2027
Figure 56: Asia Pacific Cholesterol Lowering Drugs Market Value Share, by Distribution Channel, 2018 and 2027
Figure 57: Asia Pacific Cholesterol Lowering Drugs Market Attractiveness, by Distribution Channel, 2019–2027
Figure 58: Latin America Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
Figure 59: Latin America Cholesterol Lowering Drugs Market Value Share, by Country/Sub-region, 2018 and 2027
Figure 60: Latin America Cholesterol Lowering Drugs Market Attractiveness, by Country/Sub-region, 2019–2027
Figure 61: Latin America Cholesterol Lowering Drugs Market Value Share, by Drug Class, 2018 and 2027
Figure 62: Latin America Cholesterol Lowering Drugs Market Attractiveness, by Drug Class, 2019–2027
Figure 63: Latin America Cholesterol Lowering Drugs Market Value Share, by Indication, 2018 and 2027
Figure 64: Latin America Cholesterol Lowering Drugs Market Attractiveness, by Indication, 2019–2027
Figure 65: Latin America Cholesterol Lowering Drugs Market Value Share, by Distribution Channel, 2018 and 2027
Figure 66: Latin America Cholesterol Lowering Drugs Market Attractiveness, by Distribution Channel, 2019–2027
Figure 67: Middle East & Africa Cholesterol Lowering Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
Figure 68: Middle East & Africa Cholesterol Lowering Drugs Market Value Share, by Country/Sub-region, 2018 and 2027
Figure 69: Middle East & Africa Cholesterol Lowering Drugs Market Attractiveness, by Country/Sub-region, 2019–2027
Figure 70: Middle East & Africa Cholesterol Lowering Drugs Market Value Share, by Drug Class, 2018 and 2027
Figure 71: Middle East & Africa Cholesterol Lowering Drugs Market Attractiveness, by Drug Class, 2019–2027
Figure 72: Middle East & Africa Cholesterol Lowering Drugs Market Value Share, by Indication, 2018 and 2027
Figure 73: Middle East & Africa Cholesterol Lowering Drugs Market Attractiveness, by Indication, 2019–2027
Figure 74: Middle East & Africa Cholesterol Lowering Drugs Market Value Share, by Distribution Channel, 2018 and 2027
Figure 75: Middle East & Africa Cholesterol Lowering Drugs Market Attractiveness, by Distribution Channel, 2019–2027
Figure 76: Market Position/Ranking Analysis, 2018, by Tier and Size of the Company
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Cholesterol Lowering Drugs Market
